{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Opioid-Free Anesthesia in Bariatric Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomized controlled trial was conducted at a tertiary care hospital."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were morbidly obese patients (BMI > 60 kg/m\u00b2) scheduled for laparoscopic gastric bypass."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomized to receive either OFA with total intravenous anesthesia (TIVA) using propofol, lidocaine, ketamine, and dexmedetomidine or standard opioid-based anesthesia."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study investigates the efficacy of opioid-free anesthesia (OFA) with multimodal analgesia in minimizing respiratory and opioid-related complications in morbidly obese patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was postoperative pain control, assessed by the visual analog scale (VAS) over 48 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded to group assignments."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 100 participants were randomized: 50 to the OFA group and 50 to the control group, with recruitment from January 2020 to June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on an intention-to-treat basis."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The OFA group experienced a shorter ICU stay and earlier discharge (mean difference = 2 days, 95% CI 1 to 3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were minimal, with 2% in the OFA group and 5% in the control group experiencing mild side effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the National Institute of Health."
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}